NFE2L2 and chronic myelogenous leukemia, BCR-ABL1 positive: In chronic myeloid leukemia (CML), Nrf2 appears to promote drug resistance and reduce apoptotic susceptibility in K-562 cells, a human erythroleukemia cell line frequently used in redox and cancer research [35].